| 作成者 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 本文言語 |
|
| 出版者 |
|
| 発行日 |
|
| 会議情報 |
|
| 出版タイプ |
|
| アクセス権 |
|
| 権利関係 |
|
|
|
| 概要 |
［Objective］Nephrotoxicity is diagnosed in 28-42% of patients applied cisplatin. Mg2+ is involved in active transport of cisplatin in proximal tubule cells, therefore, we retrospectively examined wheth...er Mg2+ supplementation prevent nephrotoxicity during cisplatin-containing chemotherapy. All patients provided written informed consent before treatment. ［Methods］Forty four patients of gynecologic cancer treated in our hospital from Oct 2014 to Sep 2015（study group）were analyzed. They were supplied magnesium sulfate containing 8mEq of Mg2+ just before cisplatin administration. Serum creatinine level（Cr：mg/dL）and glomerular filtration rate（GFR：mL/min）were examined before and after treatment. These laboratory data were compared with those of 74 patients treated previously without Mg2+ supplementation（control group）. ［Results］Statistically significant Cr elevation（+0.11±0.17 vs -0.03±0.10）and GFR decrease（-13.0±22.2 vs+2.2±17.6）were found in control group compared with study group（p＜0.001）. Discontinuation of chemotherapy occurred in 8 cases in control group due to renal dysfunction. However, all patients in study group could receive scheduled treatment. ［Conclusion］Magnesium sulfate supplementation might be effective for renal protection during cisplatin-containing chemotherapy.続きを見る
|
Mendeley出力
